Larson Financial Group LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA)

Larson Financial Group LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 39.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,266 shares of the company’s stock after acquiring an additional 356 shares during the quarter. Larson Financial Group LLC’s holdings in Moderna were worth $53,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. State Street Corp increased its holdings in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after acquiring an additional 178,115 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after acquiring an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. UBS Group decreased their target price on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $60.63.

Moderna Trading Up 3.7 %

Shares of MRNA stock opened at $35.01 on Thursday. The company has a market cap of $13.51 billion, a price-to-earnings ratio of -3.77 and a beta of 1.86. The stock has a 50 day simple moving average of $36.25 and a 200-day simple moving average of $48.01. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.